{"id":49570,"date":"2026-06-02T11:35:30","date_gmt":"2026-06-02T11:35:30","guid":{"rendered":"https:\/\/quickassetsmarket.com\/index.php\/2026\/06\/02\/abivax-stock-crashes-as-safety-fears-overshadow-bowel-disease-drug-trial-win\/"},"modified":"2026-06-02T11:35:30","modified_gmt":"2026-06-02T11:35:30","slug":"abivax-stock-crashes-as-safety-fears-overshadow-bowel-disease-drug-trial-win","status":"publish","type":"post","link":"https:\/\/quickassetsmarket.com\/index.php\/2026\/06\/02\/abivax-stock-crashes-as-safety-fears-overshadow-bowel-disease-drug-trial-win\/","title":{"rendered":"Abivax stock crashes as safety fears overshadow bowel disease drug trial win"},"content":{"rendered":"
<\/div>\n

Abivax shares fell 31% even after the French biotech reported strong late-stage data for obefazimod, its experimental treatment for ulcerative colitis. <\/p>\n

The once-daily oral therapy met the main goal and all key secondary endpoints in a Phase 3 maintenance study, strengthening the case for a potential new option in a market still led by injectable biologics and other advanced treatments. <\/p>\n

But the stock reaction showed that investors were not looking at efficacy alone. <\/p>\n

They also focused on cancer cases reported in the higher-dose group, even though trial investigators judged them unrelated to the drug.<\/p>\n

Abivax stock: Trial win puts obefazimod in focus<\/h2>\n

The key result came from Abivax\u2019s Phase 3 ABTECT maintenance trial, which tested 25 mg and 50 mg once-daily doses of obefazimod in patients with moderately to severely active ulcerative colitis.<\/p>\n

These were patients who had already responded after the induction phase of treatment. <\/p>\n

The maintenance study then asked a more important long-term question: could the drug keep patients well over time?<\/p>\n

At week 44, clinical remission rates reached 50.8% in the 25 mg group and 51.3% in the 50 mg group.<\/p>\n

That compared with a placebo remission rate of 10.4%. On a placebo-adjusted basis, Abivax reported remission differences of 39.3 percentage points for the lower dose and 40.3 percentage points for the higher dose.<\/p>\n

Both doses met the US FDA primary endpoint for clinical remission. <\/p>\n

Abivax also said the trial met all key secondary endpoints, including endoscopic improvement, endoscopic remission, corticosteroid-free clinical remission and sustained clinical remission.<\/p>\n

For investors, this matters because ulcerative colitis is a chronic disease. Short-term symptom relief can lift a stock for a day. <\/p>\n

Durable remission over 44 weeks can change how analysts model a drug\u2019s commercial potential.<\/p>\n

Analysts see a best-case readout<\/h2>\n

The strength of the data drew a bullish response from Leerink Partners analyst Thomas Smith<\/a>, who described the outcome as a \u201cbest-case\u201d scenario for Abivax.<\/p>\n

Smith said the drug had shown the best placebo-adjusted clinical remission rates reported in a large Phase 3 ulcerative colitis study. <\/p>\n

He also pointed to the low placebo remission rate, saying it \u201cunderscores the robustness of the treatment effect\u201d in this type of maintenance trial.<\/p>\n

That point is important as in clinical trials, a high placebo response can make it harder to show a drug\u2019s true effect. <\/p>\n

Here, the gap between obefazimod and placebo was wide, giving bulls a clearer argument that the drug is doing meaningful work.<\/p>\n

Smith also cited the \u201cbreadth and consistency\u201d of benefits across endpoints as clinically meaningful, especially because the effect lasted through 44 weeks of maintenance treatment. <\/p>\n

He rates Abivax “Outperform”.<\/p>\n

Other analysts’ views have also helped support the broader investment case. <\/p>\n

Citizens has carried a Market Outperform rating, while Guggenheim has maintained a Buy rating with a $175 target. <\/p>\n

That does not remove risk, but it shows why investors had treated this readout as one of the most important biotech catalysts of the year.<\/p>\n

Safety questions complicate the story<\/h2>\n

The trial win does not mean the debate is over.<\/p>\n

Biotech stocks often react violently when strong efficacy data arrive alongside any safety question. <\/p>\n

In Abivax\u2019s case, investors focused on malignancy cases reported in the 50 mg group, including prostate, breast and colon cancer cases. Abivax said investigators judged those cases unrelated to treatment.<\/p>\n

That distinction matters, but markets rarely ignore cancer disclosures in a long-term inflammatory disease setting. <\/p>\n

If a drug is meant to be taken over extended periods, doctors, regulators and investors will want a high level of confidence in its safety profile.<\/p>\n

Abivax has said obefazimod showed a favourable safety profile over the 44-week maintenance trial and reported no new safety signals. <\/p>\n

The company also plans to submit a New Drug Application to the US FDA in late 2026, making regulatory review the next major test for the programme.<\/p>\n

The post Abivax stock crashes as safety fears overshadow bowel disease drug trial win<\/a> appeared first on Invezz<\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Abivax shares fell 31% even after the French biotech reported strong late-stage data for obefazimod, its experimental treatment for ulcerative colitis. The once-daily oral therapy met the main goal and all key secondary endpoints in a Phase 3 maintenance study, strengthening the case for a potential new option in a market still led by injectable <\/p>\n","protected":false},"author":1,"featured_media":49571,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-49570","post","type-post","status-publish","format-standard","has-post-thumbnail","category-investing"],"_links":{"self":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts\/49570","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/comments?post=49570"}],"version-history":[{"count":0,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts\/49570\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/media\/49571"}],"wp:attachment":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/media?parent=49570"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/categories?post=49570"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/tags?post=49570"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}